UBS Group
BIAFW icon

UBS Group’s bioAffinity Technologies BIAFW Stock Holding History

UBS Group’s Portfolio BIAFW Stock Details BIAFW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.5K Buy
46,445
+336
+0.7% +$87 ﹤0.01% 8830
2026
Q1 		$20.9K Sell
46,109
-440
-0.9% -$140 ﹤0.01% 7900
2025
Q4 		$16.3K Sell
46,549
-1,120
-2% -$400 ﹤0.01% 7920
2025
Q3 		$15.7K Sell
47,669
-903
-2% -$128 ﹤0.01% 8308
2025
Q2 		$6.31K Buy
48,572
+289
+0.6% +$51 ﹤0.01% 9103
2025
Q1 		$9.17K Buy
48,283
+47,618
+7,161% +$19.7K ﹤0.01% 8705
2024
Q4 		$199 Buy
665
+198
+42% +$167 ﹤0.01% 9576
2024
Q3 		$537 Buy
+467
New +$485 ﹤0.01% 8905
2023
Q3 		– Sell
-285
Closed -$60 – 9466
2023
Q2 		$60 Buy
+285
New +$88 ﹤0.01% 8579
2023
Q1 		– Sell
-66
Closed -$28 – 9615
2022
Q4 		$28 Sell
66
-11,646
-99% -$5.13K ﹤0.01% 10531
2022
Q3 		$4K Buy
+11,712
New +$12.1K ﹤0.01% 9331

Other funds holding BIAFW

CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

UBS Group's BIAFW Position: Q2 2026 in Review

UBS Group increased its bioAffinity Technologies (BIAFW) stake by 0.73% in Q2 2026, buying an estimated $87 and bringing the position to 46,445 shares worth $6.5K. The position accounts for ﹤0.01% of the portfolio, ranked #8830.

UBS Group first reported a position in BIAFW in Q3 2022 and has held it in 11 quarters since. The position peaked at $20.9K in Q1 2026. 4 funds tracked by Wall St. Rank hold BIAFW as of Q2 2026.

  • UBS Group held 46,445 shares of bioAffinity Technologies worth $6.5K as of Q2 2026.
  • UBS Group bought 336 bioAffinity Technologies shares in Q2 2026, an estimated $87.
  • bioAffinity Technologies made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8830 holding.
  • UBS Group first reported a position in bioAffinity Technologies in Q3 2022 and has held it in 11 quarters since.
  • UBS Group's bioAffinity Technologies position peaked at $20.9K in Q1 2026.
  • 4 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.